Abstract | BACKGROUND: METHODS: First, three patients were administered 70 mg/m2 of cisplatin intravenously on day 1 and 60 mg/m2 of CPT-11 intravenously on days 1, 8 and 15. Treatment was repeated every 4 weeks. Other patients were administered 75 mg/m2 of cisplatin intraperitoneally on day 1 and 60 mg/m2 of CPT-11 intravenously on days 1, 8 and 15. Treatment was repeated every 4 weeks. RESULTS: A total of 10 patients were entered in this study and a total of 43 courses were administered. 1 CR, 1 PR and 1 PD were observed in patients with measurable lesion. Grade 3 leukopenia was experienced in seven patients, grade 3 thrombocytopenia in two and grade 3 anemia in five. Grade 3 liver toxicity was observed in one patient and grade 3 diarrhea in one patient. No grade 4 toxicity was experienced. CONCLUSION:
|
Authors | S Adachi, T Ogasawara, N Yamasaki, H Shibahara, R Kanazawa, Y Tsuji, T Takemura, K Koyama |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 29
Issue 9
Pg. 434-7
(Sep 1999)
ISSN: 0368-2811 [Print] England |
PMID | 10563197
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Irinotecan
- Cisplatin
- Camptothecin
|
Topics |
- Adenocarcinoma, Clear Cell
(drug therapy)
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Cisplatin
(administration & dosage)
- Drug Administration Schedule
- Female
- Humans
- Irinotecan
- Middle Aged
- Ovarian Neoplasms
(drug therapy)
- Pilot Projects
|